Entrada Therapeutics (TRDA) to Release Earnings on Thursday
Entrada Therapeutics (NASDAQ:TRDA) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts forecasting a loss of ($1.06) per share and revenue of $7.41 million. The company's stock opened at $11.04, has a market cap of approximately $422 million, and holds a "Moderate Buy" consensus rating from analysts with an average target price of $18.50. Insider activity shows the CFO sold shares, and institutional investors hold a significant stake in the company.
Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline
Entrada Therapeutics, Inc. (TRDA) is projected to report a significant year-over-year decline in Q4 earnings and revenues for the quarter ended December 2025. The Zacks Consensus Estimate predicts a loss of $1.32 per share, a 4500% decrease, and revenues of $1.29 million, down 96.6%. The company currently has a Zacks Rank #3 and a negative Earnings ESP of -59.09%, making an earnings beat difficult to predict.
Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline
Entrada Therapeutics, Inc. (TRDA) is projected to report a significant year-over-year decline in Q4 earnings and revenues for the quarter ending December 2025. The company is expected to post a quarterly loss of $1.32 per share, with revenues anticipated to be $1.29 million, down 96.6% from the prior year. Analysts have recently become more bearish on TRDA's earnings prospects, resulting in an Earnings ESP of -59.09% and a Zacks Rank of #3, making a positive EPS surprise unlikely.
HC Wainwright & Co. Reiterates Buy Rating on TRDA with $20 PT
HC Wainwright & Co. has reiterated its 'Buy' rating for Entrada Therapeutics (TRDA) with a consistent target price of $20.00 USD. This aligns with a previous rating in May 2025 and an initiated 'Buy' rating from Guggenheim in February 2026, also at a $20.00 target. The average Wall Street analyst forecast for TRDA is $18.50, indicating a potential 67.72% upside from its current price, despite GuruFocus estimating a downside based on its GF Value.
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study
Entrada Therapeutics announced that an independent Data Monitoring Committee recommended initiating Cohort 2 of its ELEVATE-44-201 study at an increased dose of 12 mg/kg, following a review of safety and PK data from Cohort 1. This study is evaluating ENTR-601-44 for Duchenne muscular dystrophy. The company expects to report Cohort 1 data in Q2 2026 and Cohort 2 data by year-end, anticipating best-in-class dystrophin restoration at higher doses.
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study
Entrada Therapeutics announced that an independent Data Monitoring Committee (DMC) has recommended the initiation of Cohort 2 at a 12 mg/kg dose in its ELEVATE-44-201 clinical study for Duchenne muscular dystrophy (DMD). This recommendation follows a review of safety and PK data from Cohort 1. The company expects to report Cohort 1 data in Q2 2026 and Cohort 2 data by year-end, aiming for best-in-class dystrophin restoration.
Duchenne drug trial doubles dose to 12 mg/kg, aims at accelerated FDA approval
Entrada Therapeutics announced that an independent Data Monitoring Committee recommended initiating Cohort 2 of its ELEVATE-44-201 Phase 1/2 study at an increased dose of 12 mg/kg, following positive safety and PK data from Cohort 1. The study is investigating ENTR-601-44 for Duchenne muscular dystrophy (DMD) and aims for accelerated FDA approval, with data from Cohort 1 expected in Q2 2026 and Cohort 2 by year-end. The company has also received Rare Pediatric Disease Designation for ENTR-601-44, further supporting its development.
Precision Trading with Entrada Therapeutics Inc. (TRDA) Risk Zones
This article from Stock Traders Daily analyzes Entrada Therapeutics Inc. (TRDA) using AI-generated signals to identify precision trading opportunities. It highlights divergent sentiment, a potential exceptional risk-reward short setup, and provides three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths with corresponding support and resistance levels.
Entrada Therapeutics (NASDAQ:TRDA) Raised to Strong-Buy at Guggenheim
Guggenheim upgraded Entrada Therapeutics (NASDAQ:TRDA) to a "strong-buy" rating. This upgrade contributes to the stock's overall "Moderate Buy" consensus and an average price target of $18.50. The article also details recent insider trading activity and institutional investor positions.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of "Hold" by Brokerages
Brokerages have given Entrada Therapeutics, Inc. (NASDAQ:TRDA) a consensus "Hold" rating, based on assessments from five analysts. The average 12-month price target for TRDA is $18.50. Insider transactions include a director selling shares and a major shareholder purchasing shares, while institutional investors hold a significant portion of the company's stock.
Revenues Working Against Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Share Price
Entrada Therapeutics (NASDAQ:TRDA) has a low price-to-sales (P/S) ratio of 5.9x, which is significantly below the biotech industry average, indicating potential bearish sentiment. This low valuation is attributed to the company's recent revenue decline of 71% and a forecasted future revenue growth of only 5.1% annually, sharply contrasting with the industry's projected 134% growth. The article suggests that while the low P/S might make it seem like a value buy, investors are likely factoring in the limited growth prospects, making a strong share price increase unlikely in the near future.
Technical Reactions to TRDA Trends in Macro Strategies
This article analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA) trends using AI models. It identifies a potential strong sentiment in the near and mid-term that could extend to the long term, with a mid-channel oscillation pattern. The analysis provides specific institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis and support/resistance levels.
Entrada Therapeutics to Present at Upcoming Investor Conferences
Entrada Therapeutics (Nasdaq: TRDA) announced its participation in two upcoming investor conferences in February and March 2026. CEO Dipal Doshi will hold fireside chats at the Guggenheim Emerging Outlook: Biotech Summit in New York and the TD Cowen 46th Annual Health Care Conference in Boston. Webcasts and replays of these events will be available on the company's Investor Relations website.
Entrada CEO Dipal Doshi to join biotech investor talks in New York, Boston
Entrada Therapeutics (Nasdaq: TRDA) announced its CEO, Dipal Doshi, will participate in two upcoming investor conferences. He is scheduled for a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, and another at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. Live webcasts and replays for both events will be available on the company's investor relations website for 90 days.
Entrada Therapeutics (NASDAQ:TRDA) Coverage Initiated by Analysts at Oppenheimer
Oppenheimer has initiated coverage on Entrada Therapeutics (NASDAQ:TRDA) with an "outperform" rating and a $21 price target, indicating a potential 90.91% upside. Despite this, analyst views are mixed, resulting in an average "Hold" rating and an $18 price target for TRDA, which trades near $11. The company recently missed EPS and revenue estimates, reported negative margins, and saw net insider selling, although institutional ownership remains high at approximately 86%.
Trading the Move, Not the Narrative: (TRDA) Edition
This article analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA), noting strong near and mid-term sentiment but a weak long-term outlook with elevated downside risk. It provides an AI-generated signal analysis and outlines three institutional trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, complete with entry zones, targets, and stop losses. The analysis emphasizes trading the move rather than the narrative using predictive AI.
(TRDA) Volatility Zones as Tactical Triggers
This article analyzes Entrada Therapeutics Inc. (TRDA) using AI models, highlighting weak sentiment across all time horizons which supports a short bias. It provides specific trading strategies including a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy with entry zones, targets, and stop losses. The analysis also details multi-timeframe signal strengths, support, and resistance levels for the stock.
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating for Entrada Therapeutics Inc., maintaining a $20 price target. This positive outlook is driven by the company's progress in its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) clinical programs, with several readouts expected soon. Additionally, Entrada's emerging ophthalmology pipeline, targeting inherited retinal disorders, contributes to the long-term growth potential.
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Down 4.8% - Should You Sell?
Entrada Therapeutics (NASDAQ:TRDA) saw its stock price drop 4.8% during mid-day trading on Friday, with only about 101,589 shares traded. The company missed earnings estimates, reporting a loss of $1.06 per share and lower-than-expected revenue of $1.61 million. Analyst sentiment is mixed, with a consensus "Hold" rating and a target price of $16.50, but fundamental indicators like negative margins and low PE ratio raise concerns.
Entrada reports progress on DMD treatments, shares clinical timeline
Entrada Therapeutics (NASDAQ:TRDA) announced significant progress in its RNA-based programs for neuromuscular and ocular diseases, including upcoming data readouts for its Duchenne muscular dystrophy (DMD) treatments in 2026. The company completed dosing for the first cohort of its exon 44 skipping DMD study and received regulatory authorization for an exon 50 skipping study in the UK. Entrada also expanded its pipeline with a new clinical candidate for Usher syndrome type 2A and anticipates a data-rich year for its Duchenne franchise.
Entrada Therapeutics highlights RNA pipeline progress and outlook
Entrada Therapeutics (TRDA) has provided an update on its RNA-based pipeline, detailing progress in therapies for Duchenne muscular dystrophy (DMD) and ocular diseases, including the selection of ENTR-801 for Usher syndrome type 2A. The company has a cash runway into Q3 2027 and will present at the J.P. Morgan Healthcare Conference, aiming to strengthen its position in genetic disease therapies. While an analyst maintains a Hold rating, TipRanks' AI Analyst, Spark, rates TRDA as Neutral due to financial challenges despite strong technical momentum.
Entrada Therapeutics Advances Clinical Pipeline and Reports Progress Amid Upcoming Data Releases and New Ocular Candidate Selection
Entrada Therapeutics announced significant progress in its clinical pipeline for neuromuscular and ocular diseases, including upcoming data releases from its Duchenne muscular dystrophy (DMD) programs (ELEVATE-44-201 and ELEVATE-45-201) in 2026. The company is expanding its pipeline by selecting ENTR-801 as its first clinical candidate for Usher syndrome type 2A and expects to nominate a second ocular candidate. Entrada also confirmed a strong financial position with a cash runway extending into Q3 2027 and will present at the J.P. Morgan Healthcare Conference.
New RNA-based drugs advance for muscular dystrophy and inherited blindness
Entrada Therapeutics announced significant clinical and preclinical progress in its RNA-based programs for neuromuscular and ocular diseases, including Duchenne muscular dystrophy (DMD) and Usher syndrome type 2A. The company expects data readouts for multiple DMD programs in 2026 and nominated ENTR-801 as its first ocular clinical candidate. Entrada Therapeutics confirms it has sufficient cash to fund operations into Q3 2027.
Price-Driven Insight from (TRDA) for Rule-Based Strategy
This article provides a price-driven insight for Entrada Therapeutics Inc. (NASDAQ: TRDA) based on AI models, indicating weak sentiment across all horizons and supporting a short bias. It outlines detailed institutional trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis highlighting support and resistance levels.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Fly 26% But Investors Aren't Buying For Growth
Entrada Therapeutics (NASDAQ:TRDA) shares have recently gained 26%, though they are still down 38% over the past year. The company's price-to-sales (P/S) ratio of 6.4x is low compared to the Biotech industry average, reflecting investor concerns over declining revenue, which fell 71% last year with a forecasted 47% annual decrease over the next three years. This weak revenue outlook and negative growth prospects explain the low P/S and suggest that the stock may not appeal to growth-focused investors despite its recent price bounce.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Fly 26% But Investors Aren't Buying For Growth
Entrada Therapeutics (NASDAQ:TRDA) shares recently gained 26%, yet its price-to-sales (P/S) ratio remains low compared to the biotech industry. This low P/S is attributed to the company's declining revenue, which dropped 71% in the last year, and a dismal future outlook with analysts forecasting a 47% per annum revenue decrease for the next three years, contrasting sharply with the industry's projected 130% growth. Investors are not buying for growth as the company's fundamentals do not support a higher valuation.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Fly 26% But Investors Aren't Buying For Growth
Entrada Therapeutics (NASDAQ:TRDA) shares have seen a 26% gain in the last month, yet are still down 38% over the past year. Its price-to-sales ratio of 6.4x is low compared to the Biotechs industry average, driven by a 71% decline in revenues over the last year and a projected 47% annual decrease in revenue by analysts for the next three years. This poor performance and grim outlook explain the low P/S and suggest investors are not confident in future growth despite the recent stock rally.
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Entrada Therapeutics, Inc. announced that its Chief Executive Officer, Dipal Doshi, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will be available via live webcast on Entrada's Investor Relations website. Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing new medicines for intracellular targets using its Endosomal Escape Vehicle (EEV™)-therapeutics.
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced that CEO Dipal Doshi will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 PM PT. A live webcast of the presentation will be available on the company's Investor Relations website and archived for 30 days. Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing new medicines for intracellular targets using its Endosomal Escape Vehicle (EEV™)-therapeutics.
5AM Venture Management LLC Has $28.95 Million Stake in Entrada Therapeutics, Inc. $TRDA
5AM Venture Management LLC has a significant stake of $28.95 million in Entrada Therapeutics, Inc. (NASDAQ:TRDA), despite trimming its position by 2.3% in the last quarter. The firm's holding represents 11.1% of its investment portfolio and 11.33% of Entrada Therapeutics. Other institutional investors like Merck & Co. Inc., Wellington Management Group LLP, and Geode Capital Management LLC have also adjusted their stakes in the biopharmaceutical company.
Trading Systems Reacting to (TRDA) Volatility
Entrada Therapeutics Inc. (NASDAQ: TRDA) is experiencing strong near and mid-term sentiment, though its long-term outlook is weak with elevated downside risk. AI-generated trading strategies for TRDA include position trading, momentum breakout, and risk hedging, tailored for different risk profiles. The analysis provides real-time signals, risk-reward ratios, and multi-timeframe updates for informed trading decisions.
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced inducement grants to five newly-hired non-executive employees comprising 40,650 restricted stock units and options to purchase 38,850 shares of common stock. These grants, effective December 1, 2025, were approved by the Compensation Committee as a material inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants are subject to vesting schedules primarily based on continued employment.
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics, Inc. announced the grant of 40,650 restricted stock units and options to purchase 38,850 shares of its common stock to five new non-executive employees. These inducement grants, effective December 1, 2025, were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) to attract and retain talent. The options and RSUs vest over a four-year period, subject to continued employment.
Baker Bros. Advisors LP Increases Stake in Entrada Therapeutics Inc.
Baker Bros. Advisors LP has increased its stake in Entrada Therapeutics Inc. by adding 28,867 shares, bringing their total to over 5 million shares. This move, executed at $9.07 per share, reflects the hedge fund's continued confidence in the biopharmaceutical company's long-term potential, despite Entrada Therapeutics' current overvaluation and financial challenges. The firm specializes in life sciences companies and is known for its fundamental-driven, concentrated investment strategy.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Average Recommendation of "Moderate Buy" by Analysts
Entrada Therapeutics, Inc. (NASDAQ:TRDA) has received an average recommendation of "Moderate Buy" from five analysts, with a 12-month average price target of $20.67. Recent insider transactions include Director Kush Parmar selling 200,000 shares and Bros. Advisors LP buying 100,736 shares. The company recently missed Q3 earnings and revenue estimates, reporting an EPS of -$1.06 against an estimate of -$1.04, and revenue of $1.61 million against an $8.62 million estimate.
William Blair Sticks to Their Buy Rating for Entrada Therapeutics Inc (TRDA)
William Blair analyst Myles Minter has reiterated a Buy rating for Entrada Therapeutics Inc (TRDA). Minter, a 5-star analyst with a 30.1% average return, focuses on the Healthcare sector, and the consensus for Entrada Therapeutics Inc is a Strong Buy with an average price target of $18.50. The company recently reported a quarterly revenue of $1.95 million and a GAAP net loss of $43.1 million for the quarter ending June 30.
Major Investment Alert: Baker Bros. Advisors LP Boosts Stake in Entrada Therapeutics!
Baker Bros. Advisors LP has increased its stake in Entrada Therapeutics Inc (TRDA) by purchasing 178,044 shares valued at $1,351,942. This investment comes despite Entrada's challenging Q3 report, which showed a net loss of $44.1 million and decreased collaboration revenue. TipRanks' AI Analyst, Spark, rates TRDA as Neutral due to financial performance challenges and unattractive valuation, even as the company anticipates value inflection points in its Duchenne muscular dystrophy programs in 2026.
Entrada Therapeutics Eyes 2026 Trial Data With Cash Runway Into 2027
Entrada Therapeutics is progressing its pipeline for neuromuscular diseases, with key trial data expected in 2026 for its Duchenne muscular dystrophy and myotonic dystrophy type 1 programs. The company projects a cash runway into Q3 2027, supported by $327 million in cash and cash equivalents as of September 30, 2025. Entrada is also expanding its preclinical work and collaboration efforts, making it a stock to watch in the rare disease treatment space.
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring A 105.99% Potential Upside
Entrada Therapeutics (TRDA) is a biotechnology company with a potential upside of 105.99% based on an average analyst target price of $16.50. Despite financial challenges common to clinical-stage biopharmaceutical firms, all analysts rate the stock as "Buy" due to its innovative Endosomal Escape Vehicle (EEV™) technology and robust development pipeline for neuromuscular and ocular diseases. The company's technical indicators suggest a mixed but potentially bullish sentiment, though it does not offer dividends, preferring to reinvest in R&D.
Bros. Advisors Lp Baker Acquires 100,736 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock
Bros. Advisors Lp Baker recently acquired 100,736 shares of Entrada Therapeutics (NASDAQ:TRDA) stock on November 12th at an average price of $7.76, increasing their total stake to 4,664,924 shares valued at approximately $36.2 million. This purchase is part of a larger buying trend by the investor, who also bought shares on November 10th and 11th. Entrada Therapeutics, a clinical-stage biotech company with a market cap of $306.14 million, has a "Moderate Buy" consensus rating from analysts, with an average price target of $20.67, despite recent negative earnings and a revenue miss.
Entrada Therapeutics Faces Losses But Keeps Wall Street’s Support
Entrada Therapeutics reported a significant net loss and reduced revenue after concluding its partnership with Vertex. Despite these financial setbacks, Wall Street analysts maintain a "buy" rating, anticipating positive clinical trial results for its Duchenne muscular dystrophy (DMD) programs by mid-2026. The company's substantial cash reserves are expected to fund research until at least Q3 2027, highlighting investor confidence in its long-term biotech potential.
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) reported a Q3 loss of $1.06 per share, missing the Zacks Consensus Estimate of a $1.04 loss and significantly underperforming its prior year's loss of $0.35 per share. The company also posted revenues of $1.61 million, falling short of the Zacks Consensus Estimate by 69.94% compared to $19.57 million a year ago. These results have led to the stock underperforming the market, with a current Zacks Rank #3 (Hold).
Entrada Therapeutics Reports Third Quarter 2025 Financial Results
Entrada Therapeutics reported its Q3 2025 financial results, highlighting significant progress in its Duchenne muscular dystrophy (DMD) clinical programs and extending its cash runway into Q3 2027. The company anticipates a data-rich year in 2026 with multiple potential catalysts from its ELEVATE-44-201 and ELEVATE-45-201 studies. Entrada aims to advance its pipeline of intracellular therapeutics, including preparations for a global Phase 1/2 study for ENTR-601-50 and expanding its preclinical efforts into ocular and metabolic diseases.
Goldman Sachs initiates coverage on Entrada Therapeutics stock with Early-Stage Biotech rating
Goldman Sachs has initiated coverage on Entrada Therapeutics (NASDAQ:TRDA) with an "Early-Stage Biotech" rating, citing the potential of its Endosomal Escape Vehicle (EEV) platform. The firm sees significant upside potential, with analyst price targets ranging from $17 to $20, despite concerns about rapid cash burn and downward earnings revisions. Entrada Therapeutics also recently awarded grants to Duchenne muscular dystrophy community organizations, while another firm, Roth/MKM, adjusted its price target to $17 but maintained a Buy rating.
$50K Each: Two Non-Profits Win Entrada's DREAMS Grants for Revolutionary Duchenne Care Programs
Entrada Therapeutics has announced the recipients of its third annual DREAMS Grant Program, awarding $50,000 each to the Jett Foundation (US) and Parent Project aps (Italy). These grants will support initiatives for underserved individuals with Duchenne muscular dystrophy, with Jett Foundation funding its Camp Promise program and Parent Project aps providing home-based care in Southern Italy. The announcement was made ahead of World Duchenne Awareness Day, and the program aims to promote equity, accessibility, and inclusion on a global scale.
5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202k
5AM Ventures V, a ten percent owner of Entrada Therapeutics, Inc. (NASDAQ: TRDA), sold 27,000 shares of common stock for a total of $202,554 on July 9, 2025. This transaction occurred as the stock trades near its 52-week low, with InvestingPro analysis suggesting it is undervalued. Meanwhile, Entrada Therapeutics has received regulatory approval to commence a Phase 1/2 clinical study in Europe and the UK for ENTR-601-45, targeting patients with Duchenne muscular dystrophy.
Entrada Therapeutics to start DMD trial in Q3 2025 By Investing.com
Entrada Therapeutics (NASDAQ:TRDA) has received authorization from EU health authorities to begin a Phase 1/2 clinical study (ELEVATE-45-201) for its Duchenne muscular dystrophy (DMD) treatment, ENTR-601-45, in Q3 2025. This investigational therapy targets exon 45 skipping in DMD patients and follows recent approval from the UK's MHRA. Despite a significant stock decline, analysts maintain a bullish outlook, and the company plans to advance its EEV™ technology pipeline for neuromuscular and ocular diseases.
Arvinas, Entrada cut staff; Merck builds US hub for Keytruda
Arvinas is laying off about a third of its workforce and discontinuing two Phase 3 studies for its breast cancer drug vepdegestrant, while Entrada Therapeutics is reducing staff by 20% to focus on Duchenne muscular dystrophy drugs. In other news, Merck & Co. has begun construction on a $1 billion facility in Delaware for biologic drugs, including Keytruda, and Scholar Rock named new executives ahead of its first drug's anticipated approval. Additionally, French regulators suspended the use of Valneva's chikungunya vaccine for individuals aged 65 and older due to adverse events.
Entrada tightens focus on Duchenne, axes 20% of staff
Entrada Therapeutics is narrowing its focus to Duchenne muscular dystrophy programs and laying off 20% of its staff. This strategic shift follows a clinical hold on its lead program, ENTR-601-44, and aims to optimize resources for its Duchenne pipeline.
FDA removes clinical hold on Entrada’s Duchenne therapy
The FDA has removed a two-year clinical hold on Entrada Therapeutics' Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, allowing the company to initiate a Phase Ib study in the US. This therapy targets adults with DMD, a demographic often excluded from clinical trials. Entrada plans to enroll patients in H1 2026, building on positive Phase I results in the UK which showed good safety and drug concentrations.
